check_circleStudy Completed

Postmenopause, Hormone Replacement Therapy

Bayer Identifier:
91203
ClinicalTrials.gov Identifier:
Not Available
EudraCT Number:
Not Available
EU CT Number:
Not Available
Study to evaluate the effect of Angeliq® and ActivelleTM on hemostasis parameters in healthy postmenopausal women

Trial purpose

Please see attached Study Results Summary below.

Key Participants Requirements

Sex

N/A

Age

N/A

Trial summary

Enrollment Goal
59
Trial Dates
December 2002 - December 2003
Phase
Phase 1
Could I Receive a placebo
N/A
Products
Angeliq (E2/DRSP, BAY86-4891)
Accepts Healthy Volunteer
N/A

Primary Outcome

Secondary Outcome

Trial design

A multi-center, open-label, randomized study to evaluate the effect of Angeliq® and ActivelleTM on hemostasis in 60 healthy postmenopausal women over 7 treatment cycles
Trial Type
Interventional
Intervention Type
N/A
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.Click here to find results for studies related to marketed products.